8
Cat No. | Product Name | Synonyms | Targets |
---|---|---|---|
T79807 | JAK kinase-IN-1 | JAK | |
JAK kinase-IN-1 (Example 1) functions as a potent inhibitor targeting the JAK family, which includes TYK2, JAK1, JAK2, and JAK3, with IC50 values of 4.2 nM, 32 nM, 27 nM, and 3473 nM, respectively [1]. | |||
T7503 | Upadacitinib | ABT-494 | JAK |
Upadacitinib (ABT-494) (ABT-494) is a selective Janus kinase (JAK) 1 inhibitor, which is being studied for the treatment of several autoimmune disorders in the IC50 of 43 nM. | |||
T82018 | JAK-IN-33 | JAK | |
JAK-IN-33 (Compound 3 (R)) is a selective inhibitor of the Janus kinase (JAK) family [1]. | |||
T79116 | JAK-IN-28 | JAK | |
JAK-IN-28 (Compound 111) is a Janus kinase (JAK) inhibitor potentially applicable in the research of cancer and inflammatory diseases [1]. | |||
T78189 | JAK-IN-26 | JAK | |
JAK-IN-26 (compound 2) is an orally active inhibitor of the Janus kinase (JAK) enzyme with favorable pharmacokinetic properties, exhibiting potency in suppressing IFN-α2B-induced STAT3 phosphorylation in Jurkat cells wit... | |||
T74800 | HAT-SIL-TG-1&AT | ||
HAT-SIL-TG-1&AT, a hypoxia-activated prodrug, functions as a Janus tyrosine kinase (JAK) inhibitor demonstrating antitumor effects by inhibiting JAK-STAT signaling within tumor tissues. It also suppresses the proliferati... | |||
T78207 | Lepzacitinib | JAK | |
Lepzacitinib, a Janus kinase inhibitor, specifically targets JAK 1/3. It demonstrates an anti-inflammatory effect and efficacy in inhibiting atopic dermatitis as well as other skin diseases [1]. | |||
T61020 | TK4b | ||
TK4b can be used in the research of leukemia cancer and lymphoid-derived diseases. TK4b is a Janus kinase (JAK) inhibitor with the IC50 values of 18.42 nM and 19.40 nM for JAK3 and JAK2, respectively [1]. |